Business Context and Reporting Period
Company: Cardio Diagnostics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 26, 2024 (Event Date)
Reporting Period: Single event date; not a periodic financial report.
Key Financial Metrics
This filing does not contain historical financial statements, revenue, profit, cash flow, or margin data. The following financial terms relate to a new financing agreement:
- Maximum Offering Size: Up to $17 million in common stock.
- Sales Agent Commission: 2.5% of gross proceeds from any sales.
- Legal Cost Cap (Initial): Up to $55,000 for the Sales Agent's legal counsel.
- Legal Cost Cap (Ongoing): Up to $5,000 per calendar quarter for diligence requirements.
- Debt/Liquidity: No specific debt or liquidity figures are provided in this text.
Material Changes
The primary material change is the entry into an At-the-Market Issuance Sales Agreement with Craig-Hallum Capital Group LLC. This agreement grants the Company the option to sell shares of its common stock through the agent as sales agent. The associated Registration Statement on Form S-3 was declared effective by the SEC on February 1, 2024.
Guidance, Outlook, and Risks
- Use of Proceeds: The Company anticipates using net proceeds for general corporate purposes, including working capital and capital expenditures.
- Uncertainty of Issuance: The Company explicitly states it cannot provide assurances that it will issue any shares pursuant to the Sales Agreement.
- Termination Rights: The Company may terminate the agreement with five business days' prior written notice. The Sales Agent may terminate at any time with written notice.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ due to market conditions and pre-sale conditions.
Investor Verification Checklist
- Verify the current market price of CDIO common stock to assess potential dilution impact if the full $17 million is sold.
- Review the Company's most recent 10-K or 10-Q for actual cash position and working capital needs to determine the necessity of this offering.
- Monitor future 8-K filings to confirm if and when shares are actually sold under this agreement.
- Check the effective Registration Statement (File No. 333-276725) for the full text of the Sales Agreement and prospectus.